Dose-adjusted EPOCH-R in MYC Positive DLBCL
Dose-adjusted EPOCH-R in MYC Positive DLBCL
The aim of this study is to evaluate the efficacy and toxicity of dose-adjusted EPOCH-R in
 patients with MYC positive diffuse large B-cell lymphoma.
The prognosis of MYC positive diffuse large B-cell lymphoma (DLBCL) is very poor even treated
 with R-CHOP regimen. Recently, dose-adjusted EPOCH-R was shown to be effective in patients
 with DLBCL and relapsed/refractory Burkitt lymphoma. The aim of this study is to evaluate the
 efficacy and toxicity of dose-adjusted EPOCH-R in patients with MYC positive diffuse large
 B-cell lymphoma.
Inclusion Criteria:

 -  Previously untreated MYC positive diffuse large B-cell lymphoma

 -  Age range 18-70 years old

 -  Eastern Cooperative Oncology Group performance status 0-2

 -  Life expectancy of more than 3 months

 -  Adequate organ function

 Exclusion Criteria:

 -  Primary or secondary central nervous system involvement

 -  Previous serious cardiac disease

 -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma
 in-situ of uterine cervix

 -  Pregnant or lactating women

 -  Serious uncontrolled diseases and intercurrent infection